Geneva, April 27 -- International Clinical Trials Registry received information related to the study (NCT07531693) titled 'Patient Relevant Outcomes Improvement Program in High Risk Hormone Receptor Positive (HR+) Breast Cancer' on April 9.

Study Type: Observational

Primary Sponsor: Institut fuer Frauengesundheit

Condition: HR+/HER2- Early Breast Cancer

Recruitment Status: Recruiting

Date of First Enrollment: February 19, 2026

Target Sample Size: 200

Countries of Recruitment: Germany

To know more, visit https://clinicaltrials.gov/study/NCT07531693

Disclaimer: Curated by HT Syndication....